A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Trial details
- Registry ID
- NCT06481891
- Phase
- Phase 3
The FDA approved Sotagliflozin (SAR439954/LX4211) on 26 May 2023.
Drug identity checked against registry records
Also recorded as SAR439954/LX4211
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyNCT06481891 | Lexicon Pharmaceuticals | Phase 3 | Active not recruiting | 2027-01Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-05-26Day | Sotagliflozin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA216203", "applicant_as_listed_by_fda": "LEXICON PHARMS INC", "brand_names": ["INPEFA"], "active_ingredients": ["SOTAGLIFLOZIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230526", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |